Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech focused on cell therapies for autoimmune diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on June 4, 2026 at 9:20 a.m. EDT. The live and archived audio webcast will be accessible via the Investors section of Artiva’s website for 90 days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ARTV
On the day this news was published, ARTV declined 0.26%, reflecting a mild negative market reaction. Argus tracked a peak move of +6.4% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $964K from the company's valuation, bringing the market cap to $369.76M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | Clinical data update | Positive | -7.7% | EULAR 2026 AlloNK data with strong ACR50 responses in refractory RA patients. |
| May 19 | Leadership change | Positive | -7.3% | Appointment of Diego Miralles as President and Head of R&D with RA focus. |
| May 08 | Equity offering | Negative | -13.0% | Pricing of common stock and pre-funded warrant offering targeting $300M proceeds. |
| May 08 | Earnings & pipeline | Positive | -13.0% | Q1 2026 report with AlloNK Phase 2a data and cash into Q2 2027. |
| May 08 | Clinical/FDA update | Positive | -13.0% | Positive AlloNK autoimmune data and FDA alignment on Phase 3 RA trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical, earnings, and leadership news has often been followed by negative price reactions, while the dilutive offering aligned with a selloff.
Over the past months, Artiva highlighted positive AlloNK clinical data and secured FDA alignment for a Phase 3 rheumatoid arthritis trial, alongside Q1 2026 results showing cash runway into Q2 2027. A sizeable underwritten offering in early May 2026 preceded notable price weakness. Subsequent leadership changes and strong EULAR 2026 data updates also saw negative reactions. Against this backdrop, the Jefferies conference participation reads as routine investor-relations activity rather than a new clinical, financial, or regulatory catalyst.
Key Terms
cell therapies medical
autoimmune diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT.
To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva regarding the potential benefits, accessibility, effectiveness, safety and design of AlloNK®; Artiva's plan to initiate a registrational Phase 3 trial for AlloNK in 2026; and Artiva's participation in the 2026 Jefferies Global Healthcare Conference. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks inherent in developing product candidates and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva's actual results to differ from current expectations are discussed in Artiva's filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com
Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
